|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Michael Amoroso||Pres, CEO & Director||571,92k||N/D||1978|
|Mr. Edward G. Carr||Sr. VP, CFO & Chief Accounting Officer||437,4k||N/D||1969|
|Mr. Brian Kevany Ph.D.||VP & Chief Technical Officer||N/D||N/D||N/D|
|Mr. Gregory Gin||VP of Investor Relations & Corp. Communications||N/D||N/D||N/D|
|Dr. Brendan M. O'Malley J.D., Ph.D.||Sr. VP & Gen. Counsel||N/D||N/D||N/D|
|Scott Santiamo||Director of Corp. Communications||N/D||N/D||N/D|
|Ms. Kristina Maximenko||VP of HR||N/D||N/D||N/D|
|Dr. Vishwas Seshadri M.B.A., Ph.D.||Sr. VP and Head of Research & Clinical Devel.||N/D||N/D||N/D|
|Mr. Scott Nogi M.B.A.||VP & Head of Bus. Operation||N/D||N/D||N/D|
|Sofia Warner||Sr. Director of Investor Relations||N/D||N/D||N/D|
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
L'ISS Governance QualityScore di Abeona Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.